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Abstract 
Background: Patients with diabetes mellitus (DM) have a higher prevalence of heart failure (HF) than those without 
it. Approximately 40 % of HF patients have DM and they tend to have poorer outcomes than those without DM. This 
study evaluated the impact of insulin therapy on mortality among acute HF patients.
Methods: A total of 1740 patients from the Korean Acute Heart Failure registry with DM were included in this study. 
The risk of all‑cause mortality according to insulin therapy was assessed using the Cox proportional hazard mod‑
els with inverse probability of treatment weighting to balance the clinical characteristics (pretreatment covariates) 
between the groups.
Results: DM patients had been treated with either oral hypoglycemic agents (OHAs) alone (n = 620), insulin alone 
(n = 682), or insulin combined with OHAs (n = 438). The insulin alone group was associated with an increased mortal‑
ity risk compared with the OHA alone group (HR = 1.41, 95 % CI 1.21–1.66]). Insulin therapy combined with OHAs 
also showed an increased mortality risk (HR = 1.29, 95 % CI 1.14–1.46) compared with the OHA alone group. Insulin 
therapy was consistently associated with increased mortality risk, regardless of the left ventricular ejection fraction 
(LVEF) or HF etiology. A significant increase in mortality was observed in patients with good glycemic control (HbA1c 
< 7.0 %) receiving insulin, whereas there was no significant association in patients with poor glycemic control (HbA1c 
≥ 7.0%).
Conclusions: Insulin therapy was found to be associated with increased mortality compared to OHAs. The insulin 
therapy was harmful especially in patients with low HbA1c levels which may suggest the necessity of specific man‑
agement strategies and blood sugar targets when using insulin in patients with HF.
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Introduction
The prevalence of diabetes mellitus (DM) has increased 
by 29% over the past decade, affecting 475 million peo-
ple worldwide in 2017 [1]. It is also a common comor-
bid condition in heart failure (HF) patients, affecting 
approximately 26–43% [2–7]. Patients with both HF and 
DM have been shown to have a poorer outcome than 




†Se Yong Jang and Jieun Jang contributed equally to this work as first 
author
15 Division of Cardiology, Department of Internal Medicine, Seoul National 
University College of Medicine, 101 Daehak‑ro, Jongno‑gu, Seoul 03080, 
South Korea
Full list of author information is available at the end of the article
Page 2 of 11Jang et al. Cardiovasc Diabetol          (2021) 20:180 
an optimal treatment strategy in order to improve their 
prognosis.
Some hypoglycemic agents used in the management 
of DM have been shown to have adverse effects in HF 
patients. Thiazolidinedione, once a bestselling hypo-
glycemic agent, is no longer recommended due to its 
fluid retention adverse effect [10, 11]. Insulin has also 
been associated with sodium retention and weight gain, 
potentially exerting harmful effects. Moreover, frequent 
insulin-related hypoglycemic events can be dangerous in 
HF patients. However, HF patients have often been pre-
scribed insulin due to failure of glycemic control with oral 
hypoglycemic agents (OHAs) and lifestyle modifications.
Although some observational data showed a worse 
prognosis related to insulin therapy, conflicting results 
exist regarding the effect of insulin therapy on HF 
patients [12–16]. However, no randomized clinical tri-
als have been conducted. Therefore, there is a need for 
large-scale, long-term studies to evaluate the effect of 
insulin therapy on HF patients. This study aimed to 
investigate the impact of insulin therapy on HF patients 
with DM using data from the Korean Acute Heart Failure 
(KorAHF) registry.
Methods
Data collection and study design
The KorAHF registry is a multicenter prospective cohort 
study conducted in ten tertiary hospitals in the Republic 
of Korea. The registry enrolled 5625 patients with acute 
HF between March 2011 and February 2014 and has been 
followed up until December 2019 [7, 17]. The patients’ 
baseline demographic data, laboratory and echocardio-
graphic data, medication history, and clinical events were 
collected using the web-based Clinical Research and 
Trial system from the Korea Disease Control and Pre-
vention Agency. All study protocols were reviewed and 
approved by the Institutional Review Board of each par-
ticipating hospital, and registered with ClinicalTrials.gov 
(NCT01389843).
Two study settings were implemented to assess the 
impact of insulin therapy on the mortality of HF patients 
with DM. The first setting compared the mortality risk 
between those treated with insulin alone and those 
treated with OHAs alone, while the other setting com-
pared the mortality risk between those with and without 
insulin therapy, regardless of combined OHAs.
Study subjects and outcome assessment
Among all KorAHF patients, 2433 with DM were identi-
fied. DM was defined through patient self-reported his-
tory, glycated hemoglobin (HbA1c) level ≥ 6.5%, or the 
presence of hypoglycemic agents at baseline. Patients 
with missing information regarding pretreatment 
covariates were excluded due to the inability to estimate 
the propensity score, which is the probability of under-
going insulin therapy. Among the 2005 eligible patients, 
only those with available data on their hypoglycemic 
agent prescription were included. Patients with DM were 
divided based on their hypoglycemic agent into OHAs 
alone (OHA-only group, n = 620), insulin alone (insulin-
only group, n = 682), or a combination of insulin and 
OHAs (all-insulin group = 438) (Additional file  1: Fig-
ure S1). Combination of insulin and OHAs group were 
defined as those who took only insulin or insulin along 
with OHAs. Information on the usage and type of DM 
medication was collected at the time of registry enroll-
ment, and the registration date was defined as the time 
of exposure. The types of OHAs used among patients in 
this study were sulfonylureas, metformin, thiazolidin-
edione, acarbose, and dipeptidyl peptidase-4 inhibitors 
(Additional file  1: Table  S1). Also, the specific types of 
insulin treatment are retrospectively reviewed and listed 
in Additional file 1: Table S2.
Patient deaths were identified by linking the Statistics 
Korea database’s death data to the registry data (among 
the study patients from 2011 to 2018). All deaths after 
registration were included in all the analyses.
Statistical analyses
The patients’ clinical characteristics, including demo-
graphics, physical and laboratory findings, HF risk fac-
tors, and management are presented as frequencies and 
percentages or means and standard deviations. Clinical 
characteristics between the OHA alone group and insulin 
alone group or combination of insulin and OHAs group 
were compared using the chi-squared test for categorical 
variables and Student’s t-test for continuous variables.
We applied the generalized boosted model to estimate 
the inverse probability treatment weight (IPTW), which 
can consider many pretreatment covariates and reflect 
the nonlinear and complex associations between pre-
treatment covariates and treatment. Pretreatment covari-
ates included age, sex, body mass index (BMI), history of 
hypertension, ischemic heart disease, atrial fibrillation, 
chronic lung disease, chronic kidney disease, cerebro-
vascular disease, systolic blood pressure, diastolic blood 
pressure, heart rate, glucose level, B-type natriuretic pep-
tide levels (BNP) ≥ 500 pg/mL, N-terminal pro-B-type 
natriuretic peptide levels (NT-proBNP) ≥ 1000  pg/mL, 
serum sodium, potassium, blood urea nitrogen, and cre-
atinine levels, New York Heart Association (NYHA) Class 
III-IV, and left ventricular ejection fraction (LVEF). Man-
agement by angiotensin-converting enzyme inhibitors 
(ACEIs), angiotensin II receptor blockers (ARBs), beta-
blockers (BB), mineralocorticoid receptor antagonists 
(MRAs), warfarin, diuretics, inotropes, and vasodilators 
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were all considered. Using standardized mean differ-
ences, propensity score matching was performed to bal-
ance the clinical characteristics (pretreatment covariates) 
between the OHA alone group and insulin alone group 
or combination of insulin and OHAs group. Imbalanced 
covariates were considered as those showing a standard-
ized mean difference > 0.1, with statistical significance 
(p < 0.05).
Association between insulin therapy and mortality risk 
was evaluated by calculating hazard ratios (HRs) and 
95 % confidence intervals based on the weighted Cox 
proportional hazard regression with IPTW. Although 
IPTW was used to obtain a pseudo-population with bal-
anced clinical characteristics between the OHA alone 
group and insulin alone group or combination of insu-
lin and OHAs group, there were still several imbalanced 
characteristics, including age, history of hypertension, 
treatment with intravenous vasodilators, and inotropic 
drugs, ACEIs, and ARBs. The imbalanced covariates were 
double-adjusted in the weighted Cox proportional haz-
ard regression model to ensure unbiased estimates in the 
model and to reduce residual confounding.
Based on the assumption that the mortality according 
to DM medication among HF patients with DM would 
differ according to age, sex, LVEF, HbA1c level, HF of 
ischemic etiology, and severity of HF, the mortality risk 
evaluation of insulin therapy compared to that of oral 
therapy was performed in a population stratified accord-
ing to age (< 65 years and ≥ 65 years), sex, etiology of HF 
(non-ischemic and ischemic), LVEF (< 40 % and ≥ 40 %), 
HbA1c level (< 7.0 % and ≥ 7.0 %), NYHA class (I-II and 
III-IV), and natriuretic peptide level (BNP and NT-
proBNP cutoffs of 500 pg/mL and 1000 pg/mL). The mor-
tality risk associated with insulin therapy with the two 
most frequently used classes of OHAs (sulfonylurea and 
metformin) was also evaluated. Statistical analyses were 
performed with an alpha error of 5 % using the R statis-




A total of 1740 patients with HF and DM were included 
in this study. Among those patients, 0.9% were diag-
nosed with type 1 DM. When comparing patients in the 
insulin alone group with those in the OHA alone group, 
patients receiving insulin were significantly more likely 
to be younger and have a lower BMI. They also had sig-
nificantly lower rates of hypertension, but higher rates of 
chronic kidney disease, and inotrope and vasodilator use 
during the index admission. Despite both groups hav-
ing similar LVEF, patients receiving insulin were signifi-
cantly more likely to have severe symptoms, apparent by 
the higher NYHA classification. The prescription rates of 
ACEI/ARBs, BBs, and MRAs were significantly lower in 
the insulin-only group (Table 1).
When comparing patients in the combination insulin 
and OHAs group with those in the OHA-only group, 
patients receiving insulin were significantly more likely to 
be younger and have a lower BMI. They were also more 
likely to have chronic kidney disease and a more severe 
NYHA class, but less likely to have hypertension and 
atrial fibrillation. Patients receiving insulin had higher 
rates of inotrope and vasodilator use during the index 
admission. The prescription rates for ACEIs/ARBs, BBs, 
and MRAs were significantly lower in the combination of 
insulin and OHAs group (Table 1).
Mortality of patients with diabetes mellitus and heart 
failure based on insulin therapy
All-cause mortality rate per 10 person-years of HF 
patients with DM were 1.45 (95% CI 1.29–1.61), 2.18 
(95% CI 1.98–2.39), and 1.98 (95% CI 1.84–2.13) in the 
OHA alone, insulin alone, and combination of insulin and 
OHAs group, respectively (Additional file 1: Table S3).
Both the insulin-only and all-insulin groups showed 
significantly higher mortality than the OHA-only group 
(HR 1.27; 95% CI 1.09–1.49 for the insulin-only group; 
HR 1.21; 95% CI 1.07–1.36 for all-insulin group, respec-
tively). After the double adjustment for the imbalanced 
covariates, both the insulin-only and all-insulin groups 
were associated with significantly higher mortality (HR 
1.41; 95% CI 1.21–1.66 for the insulin-only group; HR 
1.29; 95% CI 1.14–1.46 for the all-insulin group) than the 
OHA-only group (Table 2).
Kaplan–Meier survival analyses with IPTW demon-
strate significantly higher mortality in both the insulin-
only and all-insulin groups than in the OHA-only group. 
(Fig. 1).
Impact of insulin therapy on the subgroups stratified 
according to age, sex, etiology of heart failure, left 
ventricular ejection fraction, and glycated hemoglobin 
level
The impact of insulin therapy on the subgroups classified 
according to age, sex, etiology of HF, LVEF, HbA1c level, 
natriuretic peptide level, and NYHA class in the setting 
of double adjustment is shown in Fig. 2. Insulin therapy 
was associated with a higher risk of mortality in both 
subgroups of patients aged < 65 years and ≥ 65 years than 
OHAs (Additional file  1: Table  S4). Male sex was asso-
ciated with significantly higher mortality in the insulin-
only and all-insulin groups than in the OHA-only group. 
However, the higher mortality in the all-insulin group 
compared to that in the OHA-only group was not statisti-
cally significant among the female population (Additional 
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file 1: Table S5). Insulin therapy was also associated with 
higher mortality than OHAs, regardless of HF etiology 
(ischemic or non-ischemic). (Additional file 1: Table S6).
Those in the insulin-only and all-insulin groups showed 
higher mortality than those in the OHA-only group 
among HF patients with reduced EF (LVEF < 40 %) (HR 
1.49; 95% CI 1.22–1.83 for insulin-only and HR 1.37; 95% 
CI 1.17–1.60 for all-insulin, respectively). For patients 
with preserved EF (LVEF ≥ 40 %), although significant 
association between combination of insulin and OHA 
therapy and mortality was not found (HR 1.19; 95% CI 
0.97–1.46), increased mortality was observed in the insu-
lin-only group (HR 1.37; 95% CI 1.05–1.78) compared to 
that in the OHA-only group. (Additional file 1: Table S7).
The impact of insulin therapy on mortality was evalu-
ated in the population stratified according to HbA1c 
levels with a cutoff of 7.0 %. In the patient subgroup 
with good glycemic control (HbA1c < 7.0 %), the insulin-
only group (HR 1.64; 95% CI 1.18–2.28) and all-insulin 
group (HR 1.59; 95% CI 1.23–2.05) were associated 
with increased mortality compared with the OHA-only 
group. However, for patients with poor glycemic con-
trol (HbA1c ≥ 7.0 %), neither the insulin-only group nor 
the all-insulin group was associated with increased mor-
tality compared with the OHA-only group (Additional 
file 1: Table S8). The impact of insulin therapy (all-insulin 
group) on mortality was significantly different according 
to HbA1c level (p-interaction < 0.01), indicating that the 
increased risk associated with insulin therapy was promi-
nent in the subgroup of patients with low HbA1c (< 7.0 %) 
(Fig. 2B). Patients with good glycemic control with com-
bined insulin and OHA therapy showed a similar mor-
tality risk to that in patients with poor glycemic control 
(HbA1c ≥ 7.0 %) with OHA therapy alone (Table 3).
  Lastly, the difference in the prognosis between the 
patients with and without insulin was tested according 
to the severity of heart failure classified using the NYHA 
class and natriuretic peptide level (Additional file  1: 
Table S9). The analysis was performed only between the 
group with OHA and all-insulin because of the small 
number of patients treated with insulin only and having 
mild symptoms (NYHA I–II) or low natriuretic peptide 
levels. In patients with NYHA class I–II, the mortality 
of all-insulin group did not differ from that with OHA 
(HR 1.03; 95% CI 0.62–1.73). However higher mortal-
ity related to insulin therapy was observed in patients 
NYHA class III–IV (HR 1.34; 95% CI 1.17–1.52). A simi-
lar trend was observed in the groups divided based on the 
natriuretic peptide level. In patients with high natriuretic 
peptide levels, insulin therapy (all-insulin group) was 
associated with worse outcomes (HR 1.27; 95% CI 1.11–
1.45), whereas the all-insulin group did not present worse 
outcomes compared to those with OHA (HR 1.05; 95% 
CI 0.76–1.47) in those with low natriuretic peptide levels. 
Overall, the results may imply that the negativeprognos-
tic impact of insulin treatment tends to be prominent in 
patients with more severely presented heart failure.
Sulfonylurea and metformin were the most frequently 
used classes of OHAs in this study. There was no signifi-
cant difference in mortality between the groups using 
sulfonylurea, metformin, or even in the case of the com-
bination of both OHAs and those treated with insulin 
(Additional file 1: Table S10).
Discussion
This study found that insulin therapy was associated with 
increased mortality in HF patients with DM, and this was 
consistent regardless of LVEF and HF etiology (ischemic 
or non-ischemic). This increase in mortality was predom-
inantly observed in patients with good glycemic control 
(HbA1c < 7.0 %) or severe degrees of HF assessed using 
the NYHA class and natriuretic peptide levels.
The current evidence regarding the effect of insu-
lin therapy on the prognosis of HF patients with DM is 
Table 2 Overall mortality according to diabetes therapy in the inverse probability of treatment weighted pseudo‑cohort within the 
KorAHF registry
N number, HR hazard ratio, CI confidence interval, OHA oral hypoglycemic agents
a Inverse probability of treatment (IPT)-weighted
b Crude HR (95% CI)
c Additionally adjusted for age, vasodilators management at admission and ACEIs/ARBs management at dischare in the first pseudo-cohort with 426 OHA group and 
682 insulin only group; adjusted for age, hypertension and inotropes and vasodilators management at admission
Original cohort Weighteda pseudo-cohort
Person-years Death (N) HR (95 % CI)b Person-years Death (N) HR (95 % CI)b  HR (95% CI)c
OHA‑only 2277 329 1.00 2277 244 1.00 1.00
Insulin‑only 1983 432 1.45 (1.26–1.67) 1983 432 1.27 (1.09–1.49) 1.41 (1.21–1.66)
OHA‑only 2277 329 1.00 2277 395 1.00 1.00
All insulin 3478 689 1.33 (1.17–1.52) 3478 689 1.21 (1.07–1.36) 1.29 (1.14–1.46)
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based on observational studies. Lawson et al. investigated 
the effect of DM on HF patients using the UK Clini-
cal Practice Research Datalink, which covers 10% of the 
UK population [12]. HF patients treated with OHAs or 
insulin had an increased risk of all-cause hospitalization 
compared to HF patients without DM. Although they did 
not directly compare the DM treatment method, insulin 
therapy showed a greater numerical risk for hospitaliza-
tion. Cooper et al. also evaluated the association between 
insulin therapy and prognosis in 35,603 patients with 
newly diagnosed DM from the Medicare claim data [14]. 
They found that patients with HF who were prescribed 
insulin had a higher incidence of death and hospitaliza-
tion than those treated with OHAs. Moreover, DM inde-
pendently predicted morbidity and mortality in chronic 
HF patients from the Candesartan in Heart Failure: 
Assessment of Reduction in Mortality and Morbidity 
program [18]. Patients with DM treated with and with-
out insulin had higher cardiovascular mortality and HF 
hospitalization rates. A recent meta-analysis by Cosmi 
et  al., which included the Valsartan Heart Failure Trial 
(Val-Heft), Controlled Rosuvastatin Multinational Trial 
in HF (CORONA), Gruppo Italiano per lo Studio della 
Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure 
(GISSI-HF), and Aliskiren Trial to Minimize Outcomes 
in Patients with Heart Failure (ATMOSPHERE), showed 
that the rate of all-cause mortality and HF hospitaliza-
tion was higher in patients with DM than in those with-
out, and the highest was for the patient group prescribed 
insulin [18–22]. In contrast to these findings, Masoudi 
et al. found no clear association between insulin use and 
the prognosis of HF patients, after having enrolled 16,417 
HF patients with DM from the Medicare data [23], and 
found that insulin therapy was not associated with the 
1-year overall mortality.
Although there is some controversy regarding the 
impact of insulin therapy on HF patients, numerous stud-
ies have described the adverse effects, other than mortal-
ity, in these patients. Skott et al. investigated the effects 
of insulin on kidney function and sodium excretion. 
They found that the increased insulin levels, induced by 
a 120-min infusion, showed a marked increase in sodium 
reabsorption, even within the physiological range [24]. 
Insulin-induced sodium and water retention are likely 
to exacerbate cardiac congestion, leading to acute HF 
decompensation and increasing the need for loop diu-
retics [24, 25]. These adverse effects can be more criti-
cal in those with severe degrees of HF. The results from 
the present study demonstrated that the adverse effect of 
insulin was prominent in patients with severe degrees of 
HF, which can be understood in the same context. The 
negative prognostic impact of insulin showed a similar 
trend in both insulin-only and all-insulin groups, indicat-
ing that the effect may be rather due to insulin itself, not 
the combination of insulin and other OHA.
In addition, insulin use increases the risk of hypogly-
cemia, which can stimulate the autonomic nervous sys-
tem as a counter-regulatory response. Laitinen et  al. 
Fig. 1 Kaplan–Meier survival curves for all‑cause mortality according to the treatment type of diabetes mellitus after inverse probability treatment 
weighting. A Insulin‑only group versus oral hypoglycemic agent (OHA)‑only group. B All‑insulin group versus OHA‑only group
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demonstrated that hyperinsulinemic hypoglycemia could 
cause a 12-fold increase in plasma epinephrine levels, 
which can induce a substantial increase in myocardial 
contractility, myocardial oxygen demand, heart rate, and 
cardiac output. These hemodynamic changes, coupled 
with a shortage of glucose supply, can be deleterious for 
patients with HF. The study conducted by Bendenis et al. 
showed an increase in hypoglycemia-induced cardio-
vascular events and an increased risk of coronary heart 
disease in patients with recent hypoglycemic events 
compared with those in patients without such events. 
The study also revealed that hypoglycemia is associated 
with systemic inflammation, inferred by the increase in 
inflammatory biomarkers [26]. In our study, the adverse 
effect of increased mortality associated with insulin ther-
apy was predominantly observed in patients with low 
HbA1c levels (< 7.0 %). Although data were not collected 
on the hypoglycemic events in our study, insulin-induced 
Fig. 2 Subgroup analysis on the association between diabetes mellitus treatment type and overall mortality. Subgroup analyses on the association 
between diabetes mellitus treatment type and overall mortality according to age, sex, etiology of heart failure, left ventricular ejection fraction, 
glycosylated hemoglobin level, natriuretic peptide level, and NYHA class after double adjustment of weighted Cox proportional hazard regression 
model. A Insulin‑only group versus oral hypoglycemic agent (OHA)‑only group (reference). B All‑insulin group versus OHA‑only group. Low BNP and 
high BNP were defined as BNP < 500 pg/mL and NT‑proBNP < 1000 pg/mL, and BNP ≥ 500 pg/mL or NT‑proBNP ≥ 1000 pg/mL, respectively
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hypoglycemic events followed by catecholamine surges 
and systemic inflammation could be a plausible expla-
nation for the increased mortality of patients with low 
HbA1c levels receiving insulin therapy. Therefore, the 
optimal timing for initiating insulin therapy, as well as the 
target level for glucose control in HF patients with DM 
might be different from patients with DM alone and war-
rants further investigation in future studies.
In the meta-analysis by Cosmi et  al. [22], the clinical 
trials Val-Heft, CORONA, and ATMOSPHERE included 
HF patients with reduced LVEF. They consistently 
showed an association between insulin use and poor 
prognosis in HF patients. The HRs for all-cause mortality 
were 1.23 (95% CI 0.98–1.55), 1.27 (95% CI 1.05–1.53), 
and 1.23 (95% CI 1.09–1.45) for Val-Heft, CORONA, and 
ATMOSPHERE, respectively. The GISSI-HF trial, which 
included HF patients regardless of LVEF, still showed an 
increased risk of mortality with insulin compared to that 
without insulin therapy (HR, 1.29; 95% CI 1.10–1.51). The 
subgroup analysis of the Treatment of Preserved Cardiac 
Function Heart Failure with an Aldosterone Antagonist 
study, which only enrolled HF patients with preserved EF 
(LVEF  ≥  45%), showed that insulin therapy was associ-
ated with a 40 % increase in all-cause and cardiovascular 
mortality compared with DM therapy without insulin 
[27]. Our study showed the adverse impact of increased 
mortality in HF patients receiving insulin therapy across 
LVEF ranges in a single study cohort [both preserved EF 
(LVEF  ≥ 40%) and reduced EF (LVEF < 40%)].
Study limitations
This study has some limitations. First, due to its obser-
vational nature, there were differences in the clinical 
characteristics between the two groups. Although we ini-
tially tried to estimate the IPTW using a logistic regres-
sion model, it was difficult to balance the characteristics 
between the untreated group and the treated group by 
using this method. Therefore, we applied the generalized 
boosted model to estimate the IPTW, which can consider 
many pretreatment covariates and reflect the nonlinear 
and complex associations between pretreatment covari-
ates and treatment. Although the Cox proportional haz-
ard model with double adjustment for the imbalanced 
variables and IPTW was performed, unmeasured con-
founding may still exist. Well-designed clinical trials will 
be needed to elucidate the adverse effect of insulin ther-
apy in patients with HF more clearly.
Second, patients taking sodium-glucose co-trans-
porter-2 (SGLT-2) inhibitors were not included as they 
were not available in clinical practice in the Republic of 
Korea during the enrollment period (2011–2014) of the 
KorAHF. Recent studies have demonstrated the benefits 
of SGLT-2 inhibitors in HF patients [28], whereas most of 
the other OHAs showed neutral effects in these patients 
Table 3 Overall mortality according to diabetes therapy in the inverse probability of treatment weighted pseudo‑cohort within the 
KorAHF registry
N number, HR hazard ratio, CI confidence interval, OHA oral hypoglycemic agents
a Inverse probability treatment (IPT)-weighted
b Crude HR (95% CI)
c Additionally adjusted for age, vasodilators management at admission and ACEIs/ARBs management at dischare in the first pseudo-cohort with 426 OHA group and 
682 insulin only group; adjusted for age, hypertension and inotropes and vasodilators management at admission
Original cohort Weighteda pseudo-cohort
Person-years Death
N
HR (95% CI)b Person-years Death
N
HR (95% CI)b HR (95% CI)c
HbA1c < 7.0%
 OHA‑only 725 85 1.00 725 60 1.00 1.00
 Insulin‑only 582 110 1.55 (1.16–2.05) 582 110 1.52 (1.11–2.09) 1.64 (1.18–2.28)
HbA1c ≥ 7.0%
 OHA‑only 661 102 1.30 (0.98–1.74) 661 71 1.58 (1.12–2.23) 1.69 (1.18–2.42)
 Insulin‑only 464 104 1.84 (1.38–2.42) 464 104 1.83 (1.33–2.52) 2.25 (1.61–3.13)
 p‑interaction 0.66 0.22 0.20
HbA1c < 7.0%
 Only oral 725 85 1.00 725 97 1.00 1.00
 All insulin 939 179 1.56 (1.20–2.02) 939 179 1.50 (1.17–1.92) 1.59 (1.23–2.05)
HbA1c ≥ 7.0%
 Only oral 661 102 1.30 (0.98–1.74) 661 123 1.52 (1.17–1.99) 1.58 (1.20–2.09)
 All insulin 1153 196 1.42 (1.10–1.83) 1153 196 1.38 (1.08–1.76) 1.57 (1.22–2.02)
 p‑interaction 0.05 0.85 < 0.01
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[29]. The inclusion of SGLT-2 inhibitors could have 
caused an analytic bias, widening the gap between insu-
lin therapy and other hypoglycemic agents. Data regard-
ing glucagon-like peptide 1 receptor agonist (GLP1RA) 
is not available either in the analysis. The reason is that 
the GLP1RA prescription rate was very low during the 
enrollment period (2011–2014) of the KorAHF registry 
because few drugs were available in Korea at that time 
and there were some limitations related to the healthcare 
system.
Third, only limited information on DM medication was 
available such as the usage and type of DM medication 
at the baseline. Although the adjustment of anti-diabetic 
treatment and patients’ adherence during the follow-up 
are also significant factors related to the prognosis, we 
could not consider them in the current analyses.
Lastly, the latency period between hypoglycemic ther-
apy and death was not considered in this study, since 
there was no information on the duration of DM medi-
cation prior to enrollment and the number of subjects 
was not sufficient to exclude those who died immediately 
after the defined drug exposure time point (enrollment 
date).
Conclusions
Insulin therapy in HF patients with DM is associated 
with a higher mortality risk than OHAs, regardless of the 
patients’ LVEF and HF etiology. The result of this paper 
suggested that insulin therapy was harmful, especially in 
patients with low HbA1c levels or more severe forms of 
heart failure; therefore, specific management strategies 
and blood sugar targets may be needed when using insu-
lin in patients with HF.
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